Skip to main content
Premium Trial:

Request an Annual Quote

Mizuho Downgrades BD to Neutral

NEW YORK (GenomeWeb News) – Mizuho Securities analyst Peter Lawson today downgraded the stock of Becton Dickinson from Buy to Neutral.

Lawson noted that BD's shares, which closed at $83.94 on the New York Stock Exchange Monday, are within 4 percent of Mizuho's $87 price target. He noted that the firm's stock has risen 9 percent over the past three months and 12 percent over the past six months and no longer trades at a discount to its historical Price-t0-earnings multiple.

"We expect low single-digit organic growth for Becton over the next two years," Lawson wrote in a note published this morning. "Becton’s life science research business (BD Bioscience, approximately 15 percent of sales) has been a drag on results for the past year and we see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish."

In addition to concerns over academic spending, Lawson cited growing diagnostic competition. However, he cited a potential new CFO, a realignment of the firm's R&D, and strengthened diagnostic positioning could serve as catalysts for the stock.

David Elkins, BD's former CFO, resigned last fall.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.